Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2014 09:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Added to the Russell Indexes

NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global,...
June 24, 2014 07:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD

Patients treated with Squalamine eye drops plus Lucentis® PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN Percentage...
June 23, 2014 16:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD

Webcast to be Held on Tuesday, June 24 at 8:30am Eastern Webcast & Slides Available at www.OhrPharmaceutical.com NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc....
June 02, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Closing of SKS Ocular Acquisition; Strengthens Executive Management Team

Jason Slakter, MD Appointed Chief Medical Officer Glenn L. Stoller, MD Appointed Chief Scientific Officer Peter K. Kaiser, MD Appointed as Senior Vice President of Product Development NEW...
May 27, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer

NEW YORK, May 27, 2014 (GLOBE NEWSWIRE) -- DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) and Cold Spring Harbor Laboratory, today announced the validation of Trodusquemine...
May 15, 2014 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Agreement to Acquire Technology Assets of SKS Ocular

Transaction Expands Ohr's Pipeline to Include Multiple New Drug Candidates in Ophthalmology Provides Ohr with Proprietary Sustained Release Drug Delivery Platform for Ocular Drugs Upfront...
May 09, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema

NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II...
April 29, 2014 05:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD

NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
April 08, 2014 09:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock

NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
March 10, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the 26th Annual ROTH Conference

NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced...